Robatumumab (Sch 717454) 是一种 anti-humanIGF-1R(胰岛素样生长因子 1 受体) 抗体。Robatumumab 具有抗肿瘤活性和抗癌细胞增殖活性。Robatumumab 可用于骨肉瘤和尤文肉瘤的研究。
| 生物活性 | Robatumumab (Sch 717454) is an anti-humanIGF-1R(insulin-like growth factorreceptor-1) antibody. Robatumumab shows anti-tumor activity and anti-proliferative activity tocancercells. Robatumumab can be used in osteosarcoma and Ewing sarcoma research[1][2]. |
体外研究
(In Vitro) | Robatumumab (0.02-80 nM; 0.5 or 4 h) downregulates IGF-IR and inhibits both basal and IGF-I-induced phosphorylation of IGF-IR and IRS-1 in SK-N-FI cells[2].
Western Blot Analysis[2] | Cell Line: | SK-N-FI cells | | Concentration: | 0.02-80 nM | | Incubation Time: | 0.5 or 4 hours | | Result: | Inhibited the IGF-I–stimulated phosphorylation of IGF-IR after treatment 0.5 h.
Resulted in both inhibition of IGF-IR phosphorylation and receptor downregulation after treatment 4 h.
Resulted in a dose-dependent inhibition of the IGF-I–stimulated IRS-1 phosphorylation. |
|
体内研究
(In Vivo) | Robatumumab (intravenous injection; 0.04 or 0.1 mg/mouse; twice weekly; 18 d) inhibits the SK-N-FI tumor growth in xenograft model[2].
Robatumumab (intravenous injection; 0.02-0.5 mg/mouse; twice weekly; 35 d) inhibits the osteosarcoma growth in xenograft model[2].
Robatumumab (intravenous injection; 0.1 or 0.5 mg/mouse; twice weekly; 14 d) inhibits the SJCRH30 and RD rhabdomyosarcoma cell growth in xenograft model[2].
Robatumumab (intravenous injection; 0.1 or 0.5 mg/mouse; twice weekly; 2 w) blocks effectively pediatric tumor cell proliferation in vivo[2].
Robatumumab (intravenous injection; 0.5 mg/mouse; once; day 11 post-inoculation) modulates the blood vessel formation via its antiangiogenesis effect[2].
| Animal Model: | Nude mice inoculated with SK-N-FI tumor cells[2] | | Dosage: | 0.04 or 0.1 mg/mouse | | Administration: | Intravenous injection; 0.04 or 0.1 mg/mouse; twice weekly; 18 days | | Result: | Inhibited the SK-N-FI xenograft tumor by 96% in the 0.04 mg dose group and resulted in 11% tumor regression in the 0.1 mg dose group. |
| Animal Model: | Nude mice inoculated with SJSA-1 osteosarcoma[2] | | Dosage: | 0.02, 0.1 or 0.5 mg/mouse | | Administration: | Intravenous injection; 0.02, 0.1 or 0.5 mg/mouse; twice weekly; 35 days | | Result: | Inhibited the tumor growth by 71%, 82%, and 88% at 0.02, 0.1, and 0.5 mg, respectively, at day 14 after treatment. |
| Animal Model: | Nude mice inoculated with SJCRH30 and RD rhabdomyosarcoma cells[2] | | Dosage: | 0.1 or 0.5 mg/mouse | | Administration: | Intravenous injection; 0.1 or 0.5 mg/mouse; twice weekly; 14 days | | Result: | Inhibited tumor growth by 39% and 58% at 0.1 and 0.5 mg dose, respectively, in the RD rhabdomyosarcoma model.
Inhibited tumor growth by 37% and 53% at 0.1 and 1 mg dose, respectively, in the SJCRH30 model. |
| Animal Model: | Nude mice inoculated with SK-N-FI neuroblastoma and SJSA-1 osteosarcoma[2] | | Dosage: | 0.1 or 0.5 mg/mouse | | Administration: | Intravenous injection; 0.1 or 0.5 mg/mouse; twice weekly; 2 weeks | | Result: | Reduced the tumor Ki-67 staining by 38% and along with significant change in SK-N-FI neuroblastoma xenograft.
Reduced the staining of Ki-67 by 37% and 51% after 0.1 and 0.5 mg SCH 717454 treatment, respectively, in the SJSA-1 osteosarcoma xenograft. |
| Animal Model: | Nude mice inoculated with SJSA-1 osteosarcoma[2] | | Dosage: | 0.5 mg/mouse | | Administration: | Intravenous injection; 0.5 mg/mouse; once; day 11 post-inoculation | | Result: | Reduced in the intensity of the fluorescent lectin staining by 74% at 0.5 mg dose, showing thinner blood vessels and reduced branches, compared with control IgG1. |
|
| Clinical Trial | |
| CAS 号 | |
| 运输条件 | Room temperature in continental US; may vary elsewhere. |
| 储存方式 | Please store the product under the recommended conditions in the Certificate of Analysis. |
m.cnreagent.com